Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-03-24
1996-01-16
Criares, T. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540521, 540522, A61K 3155, A61K 31535
Patent
active
054847834
ABSTRACT:
The present invention relates to the use of certain mercaptoacetylamide and benzazapine derivatives in treating patients suffering from hypertriglyceridemia, atherosclerosis and hypercholesterolemia.
REFERENCES:
patent: 3334091 (1967-07-01), Houlihan
patent: 3334095 (1967-08-01), Houluhan
patent: 4080449 (1978-03-01), Croisier et al.
patent: 4320057 (1982-03-01), Freed et al.
patent: 4391752 (1983-07-01), Crossley
patent: 4399136 (1983-08-01), Hassall et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 4487929 (1984-12-01), Hassall et al.
patent: 4512924 (1985-04-01), Attwood et al.
patent: 4584294 (1986-04-01), Ruyle
patent: 4658024 (1987-04-01), Attwood et al.
patent: 4692438 (1987-09-01), Hassall et al.
patent: 4716232 (1987-12-01), Ternansky
patent: 4734504 (1988-03-01), Holmes
patent: 4734505 (1988-03-01), Holmes
patent: 4762924 (1988-08-01), Hassall et al.
patent: 4772701 (1988-09-01), Attwood et al.
patent: 4782149 (1988-11-01), Lawton et al.
patent: 4785093 (1988-11-01), Hassall et al.
patent: 4808713 (1989-02-01), Attwood et al.
patent: 4824832 (1989-04-01), Flynn et al.
patent: 4826980 (1989-05-01), Hassall et al.
patent: 4973585 (1990-11-01), Flynn et al.
patent: 5208230 (1993-05-01), Flynn et al.
patent: 5238932 (1994-07-01), Flynn et al.
Davis, Harry R. et al., Supplement I Circulation, vol. 86, No. 4 p. I-220 (0873), (Oct. 1992).
Powell Jerry S. et al., Journal of American College of Cardiology, vol. 17, No. 6, pp. 137B-142B (May 1991).
Flynn, et al., J. Am. Chem. Soc. 109, 7914 (1987).
Flynn, et al., Peptide Chemistry (1987); T. Shiba & Sakakibara (ed.), Protein Research Foundation, Osaka (1988).
Flynn, et al., Tetrahedron Letters, vol. 31 (6), 815-88 (1990).
Attwood, et al., J. Chem. Soc. Perkin Trans. I, pp. 1011-1019 (1986).
Natoff, et al., Drugs of the Future, vol. 12 (5): 475-483 (1987).
J. Med. Chem. 1992, 35, 823-832, Timothy D. Ocain et al.
Bioorganic and Medical Chem. Letters vo. 1, 309, 1991.
Fournie-Zaluski, Marie-Claude et al., J. Med. Chem., 1992 vol. 35, pp. 2473-2481.
Fournie-Zaluski, Marie-Claude et al., J. Med. Chem., 1992 vol. 35, pp. 1259-1266.
French, John F., Jour. of Pharm and Exper. Therapeutics, vol. 268, No. 1, pp. 180-186 1993.
W. H. Parsons et al. Biochemical and Biophysical Research Communications vol. 117, No. 1, 1993 (Nov. 30, 1983).
Kuglyama et al., Circulation "Abstract from the 66th Scientific Sessions" 88(4), 1993, p. I-521.
Burkholder, et al. Bioorganic and Medical Chem. Letters, vol. 3, No. 2, pp. 231-234, 1993.
Flynn et al., J. Med. Chem. 1993, 36 2420-2423.
Remington's Pharmaceutical Services (1980), 16th Edition, Mack Publishing Co. pp. 420-427.
Dage Richard C.
Flynn Gary A.
French John F.
Barney Charlotte L.
Criares T. J.
Merrell Dow Pharmaceuticals Inc.
LandOfFree
Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309501